Cargando…

GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells

AIMS/HYPOTHESIS: Antigen-specific therapy aims to modify inflammatory T cell responses in type 1 diabetes and restore immune tolerance. One strategy employs GAD65 conjugated to aluminium hydroxide (GAD-alum) to take advantage of the T helper (Th)2-biasing adjuvant properties of alum and thereby regu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arif, Sefina, Gomez-Tourino, Iria, Kamra, Yogesh, Pujol-Autonell, Irma, Hanton, Emily, Tree, Timothy, Melandri, Daisy, Hull, Caroline, Wherrett, Diane K., Beam, Craig, Roep, Bart O., Lorenc, Anna, Peakman, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228993/ https://www.ncbi.nlm.nih.gov/pubmed/32248243 http://dx.doi.org/10.1007/s00125-020-05130-7

Ejemplares similares

Mapping T Cell Responses to Native and Neo-Islet Antigen Epitopes in at Risk and Type 1 Diabetes Subjects
por: Arif, Sefina, et al.
Publicado: (2021)

T cell receptor β-chains display abnormal shortening and repertoire sharing in type 1 diabetes
por: Gomez-Tourino, Iria, et al.
Publicado: (2017)

Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetes
por: Hannelius, Ulf, et al.
Publicado: (2020)

Naturally Arising Human CD4 T-Cells That Recognize Islet Autoantigens and Secrete Interleukin-10 Regulate Proinflammatory T-Cell Responses via Linked Suppression
por: Tree, Timothy I.M., et al.
Publicado: (2010)

Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD(65)-induced immune response
por: Tavira, Beatriz, et al.
Publicado: (2017)

GABA and Combined GABA with GAD65-Alum Treatment Alters Th1 Cytokine Responses of PBMCs from Children with Recent-Onset Type 1 Diabetes
por: Heath, Katie E., et al.
Publicado: (2023)

Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes
por: Liu, Yuk-Fun, et al.
Publicado: (2022)

Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes
por: Herold, Kevan C., et al.
Publicado: (2009)

In vivo preactivated autoreactive Th cells in healthy individuals
por: Radbruch, A, et al.
Publicado: (2001)

Transgenically Induced GAD Tolerance Curtails the Development of Early β-Cell Autoreactivities but Causes the Subsequent Development of Supernormal Autoreactivities to Other β-Cell Antigens
por: Tian, Jide, et al.
Publicado: (2009)

Long-Lasting Immune Responses 4 Years after GAD-Alum Treatment in Children with Type 1 Diabetes
por: Axelsson, Stina, et al.
Publicado: (2011)

Artificial Antigen Presenting Cells for Detection and Desensitization of Autoreactive T cells Associated with Type 1 Diabetes
por: Artzy-Schnirman, Arbel, et al.
Publicado: (2022)

Detection of GAD65 Autoreactive T-Cells by HLA Class I Tetramers in Type 1 Diabetic Patients
por: Giuliani, Laura, et al.
Publicado: (2009)

Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
por: Nowak, Christoph, et al.
Publicado: (2022)

Tracking immunodynamics by identification of S-G(2)/M-phase T cells in human peripheral blood()()
por: Muñoz-Ruiz, Miguel, et al.
Publicado: (2020)

16th Scottish Universities Summer School in Physics
por: Harper, Philip G, et al.
Publicado: (1977)

Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial
por: Axelsson, Stina, et al.
Publicado: (2013)

Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies
por: Salami, Falastin, et al.
Publicado: (2022)

Modulation of Immune Response against Tumor Cells by the in vivo Administration of an Autoreactive Th Clone
por: Kubo, Masato, et al.
Publicado: (1989)

Self-Glycolipids Modulate Dendritic Cells Changing the Cytokine Profiles of Committed Autoreactive T Cells
por: Buschard, Karsten, et al.
Publicado: (2012)

Alum Pastilles
Publicado: (1860)

Alum as an Emetic
Publicado: (1854)

Is Alum Poisonous?
Publicado: (1879)

Alum in Pertusis
Publicado: (1847)

Alum as an Emetic
Publicado: (1854)

Bougies with Alum
Publicado: (1845)

Latent Autoimmune Diabetes in Adults: Background, Safety and Feasibility of an Ongoing Pilot Study With Intra-Lymphatic Injections of GAD-Alum and Oral Vitamin D
por: Björklund, Anneli, et al.
Publicado: (2022)

Regulatory T cell dysfunction in type 1 diabetes: what’s broken and how can we fix it?
por: Hull, Caroline M., et al.
Publicado: (2017)

Simultaneous Detection of Circulating Autoreactive CD8(+) T-Cells Specific for Different Islet Cell–Associated Epitopes Using Combinatorial MHC Multimers
por: Velthuis, Jurjen H., et al.
Publicado: (2010)

Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells
por: Kang, Hee-Kap, et al.
Publicado: (2009)

How alum works
por: Bashyam, Hema
Publicado: (2008)

Alum Injection for Dysentery
Publicado: (1890)

Ammonia Iron Alum
por: Kemp,, et al.
Publicado: (1868)

Alum in Typhoid Fever
Publicado: (1888)

Alum Baking Powders
Publicado: (1914)

Iron and Alum Mass
Publicado: (1877)

An Experimental Study of the Anti-oxidant and the Anti-inflammatory Effects of Alum and Burnt Alum
por: Seo, Hyung-Sik
Publicado: (2012)

Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)
por: Casas, Rosaura, et al.
Publicado: (2022)

Good MRI images: to Gad or not to Gad?
por: Steen, Henning, et al.
Publicado: (2007)

GPRC6A mediates Alum-induced Nlrp3 inflammasome activation but limits Th2 type antibody responses
por: Quandt, Dagmar, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_igs9dl7j17pq5c201c39p40qpk